This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
== Access == The library is open for academic research to anyone with a Reader Identification Card. One may not remove library items from the reading rooms or the library buildings. Most of the library's general collection of books and journals are in the closed stacks of the Jefferson and Adams Buildings; specialized collections of books and other materials are in closed stacks in all three main library buildings, or are stored off-site. Access to the closed stacks is not permitted under any circumstances, except to authorized library staff, and occasionally, to dignitaries. Only the reading room reference collections are on open shelves. Since 1902, American libraries have been able to request books and other items through interlibrary loan from the Library of Congress if these items are not readily available elsewhere. Through this system, the Library of Congress has served as a "library of last resort", according to Herbert Putnam, the librarian of Congress from 1899 to 1939. The Library of Congress lends books to other libraries with the stipulation that they be used only inside the borrowing library. In 2017, the Library of Congress began development on a reader's card for children under the age of sixteen.
The supply of PUFAs for ferroptosis also depends on glutaminolysis — the uptake of glutamine via membrane transporters SLC38A1 and SLC1A5, its conversion to α-ketoglutarate, and subsequent mitochondrial catabolism to generate acetyl-CoA for fatty acid synthesis. This process is regulated by AMP-activated protein kinase (AMPK), which plays a dual role in ferroptosis through phosphorylation of either Beclin-1 or acetyl-CoA carboxylase. Under stress conditions, lipid droplets can also release free fatty acids, further amplifying lipid peroxidation. Ferroptosis has been shown to involve distinct cellular organelles, which includes peroxisomes, mitochondria, the endoplasmic reticulum (ER) and lysosomes. It has been a debate in the scientific community as to where ferroptosis is initiated in the cell, and now research points to the lysosome, where the chemical environment (iron, pH an hydrogen peroxide) are favorable. Oxidation of phospholipids can occur when free radicals abstract electrons from a lipid molecule (typically affecting polyunsaturated fatty acids), thereby promoting their oxidation. The primary cellular mechanism of protection against ferroptosis is mediated by the selenoprotein GPX4, a glutathione-dependent hydroperoxidase that converts lipid hydroperoxides into non-toxic lipid alcohols. The abundant lipid soluble vitamin α-tocopherol complements GPX4 by acting as a radical-trapping antioxidant for lipid peroxyl radicals, the chief membrane damaging species in ferroptosis that cannot be reduced by GPX4.
In the United States, the Food and Drug Administration (FDA) is responsible for creating guidelines for the approval and use of drugs. The FDA requires that all approved drugs fulfill two requirements:
== Radioactive, primordial, and stable isotopes == Some isotopes/nuclides are radioactive, and are therefore called radioisotopes or radionuclides, whereas others have never been observed to decay radioactively and are called stable isotopes or stable nuclides. For example, 14C is a radioactive form of carbon, while 12C and 13C are stable isotopes. There are about 339 naturally occurring nuclides on Earth, of which 286 are primordial nuclides, meaning that they have existed since the Solar System's formation. Primordial nuclides include 35 nuclides with very long half-lives (over 100 million years) and 251 that are considered "stable nuclides", as they have not been observed to decay. In most cases, if an element has stable isotopes, those isotopes predominate in the elemental abundance found on Earth and in the Solar System. However, in the cases of three elements (tellurium, indium, and rhenium) the most abundant isotope found in nature is actually one (or two) extremely long-lived radioisotope(s) of the element, despite these elements having one or more stable isotopes. Theory predicts that many apparently "stable" nuclides are radioactive, with extremely long half-lives (discounting the possibility of proton decay, which would make all nuclides ultimately unstable). Some stable nuclides are in theory energetically susceptible to other known forms of decay, such as alpha decay or double beta decay, but no decay products have yet been observed, and so these isotopes are said to be "observationally stable".
== Chemistry == Omeprazole contains a tricoordinated sulfinyl sulfur in a pyramidal structure and therefore can exist as either the (S)- or (R)-enantiomers. Omeprazole is a racemate, an equal mixture of the two.
Sources: en.wikipedia.org
Prem Narain Saxena (15 October 1925 – 29 November 1999) was the Founder Professor and Chairman of the Department of Pharmacology, Jawaharlal Nehru Medical College, India. He made contributions to the fields of traditional medicine and neuropharmacology. His demonstration of the wound-healing property of Curcuma longa was a major contributor to India's successful challenge of the US patent on the wound-healing property of Haldi. He was involved in discovery and pre-clinical development of the non-barbiturate hypnotic Methaqualone. His basic studies have helped in understanding the role of various neurotransmitters in thermoregulation. He also standardized the use of Setaria cervi for discovery of new anti-filarial agents.
In geology, hotspots (or hot spots) are volcanic locales thought to be fed by underlying mantle that is anomalously hot compared with the surrounding mantle. Examples include the Hawaii, Iceland, and Yellowstone hotspots. A hotspot's position on the Earth's surface is independent of tectonic plate boundaries, and so hotspots may create a chain of volcanoes as the plates move above them. There are two hypotheses that attempt to explain their origins. One suggests that hotspots are due to mantle plumes that rise as thermal diapirs from the core–mantle boundary. The alternative plate theory is that the mantle source beneath a hotspot is not anomalously hot, rather the crust above is unusually weak or thin, so that lithospheric extension permits the passive rising of melt from shallow depths.
A typical nuclear submarine has a crew of over 80; conventional boats typically have fewer than 40. The conditions on a submarine can be difficult because crew members must work in isolation for long periods of time, without family contact, and in cramped conditions. Submarines normally maintain radio silence to avoid detection. Operating a submarine is dangerous, even in peacetime, and many submarines have been lost in accidents.
Protactinium(V) chloride has a polymeric structure of monoclinic symmetry. There, within one polymeric chain, all chlorine atoms lie in one graphite-like plane and form planar pentagons around the protactinium ions. The 7-coordination of protactinium originates from the five chlorine atoms and two bonds to protactinium atoms belonging to the nearby chains. It easily hydrolyzes in water. It melts at 300 °C and sublimates at even lower temperatures. Protactinium(V) fluoride can be prepared by reacting protactinium oxide with either bromine pentafluoride or bromine trifluoride at about 600 °C, and protactinium(IV) fluoride is obtained from the oxide and a mixture of hydrogen and hydrogen fluoride at 600 °C; a large excess of hydrogen is required to remove atmospheric oxygen leaks into the reaction. Protactinium(V) chloride is prepared by reacting protactinium oxide with carbon tetrachloride at temperatures of 200–300 °C. The by-products (such as PaOCl3) are removed by fractional sublimation. Reduction of protactinium(V) chloride with hydrogen at about 800 °C yields protactinium(IV) chloride – a yellow-green solid that sublimes in vacuum at 400 °C. It can also be obtained directly from protactinium dioxide by treating it with carbon tetrachloride at 400 °C. Protactinium bromides are produced by the action of aluminium bromide, hydrogen bromide, carbon tetrabromide, or a mixture of hydrogen bromide and thionyl bromide on protactinium oxide. They can alternatively be produced by reacting protactinium pentachloride with hydrogen bromide or thionyl bromide.
=== Adipose tissue === Apelin is expressed and secreted by adipocytes, and its production is increased during adipocyte differentiation and is stimulated by insulin. Most obese people have elevated levels of insulin, which may therefore be the reason why obese people have been reported to also have elevated levels of apelin.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.